Clinical Trials
7 trialsNCT07530445 2026-04-15
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07286253 2025-12-16
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Recruiting
NCT07243691 2025-11-24
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
Sir Run Run Shaw Hospital
Phase NA Recruiting
NCT06490718 2025-09-08
Comparing Quality of Recovery Between ESPB and IV Lidocaine After Major Breast Cancer Surgery
Chinese University of Hong Kong
Phase NA Completed
NCT06505837 2025-08-28
JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Active not recruiting
NCT05894889 2025-07-23
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
Peking University
Phase 2 Active not recruiting
NCT07024030 2025-06-17
DGPR1008
The Affiliated Hospital of Qingdao University
Phase 2 Completed